BC
PCRX icon

Broadfin Capital’s Pacira BioSciences PCRX Stock Holding History

Broadfin Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-150,000
Closed -$4.84M – 58
2016
Q4 		$4.84M Hold
150,000
– – 0.54% 44
2016
Q3 		$5.13M Buy
+150,000
New +$5.88M 0.46% 54

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Broadfin Capital's PCRX Position: Q2 2018 in Review

Broadfin Capital sold out of Pacira BioSciences (PCRX) in Q2 2018, closing a stake of 166,500 shares — an estimated $5.19M sold.

Broadfin Capital first reported a position in PCRX in Q2 2016 and held it in 4 quarters. The position peaked at $5.19M in Q1 2018. 156 funds tracked by Wall St. Rank hold PCRX as of Q2 2018.

  • Broadfin Capital reported no remaining Pacira BioSciences position as of Q2 2018 after selling out during the quarter.
  • Broadfin Capital sold 166,500 Pacira BioSciences shares in Q2 2018, an estimated $5.19M.
  • Broadfin Capital first reported a position in Pacira BioSciences in Q2 2016 and held it in 4 quarters.
  • Broadfin Capital's Pacira BioSciences position peaked at $5.19M in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2018.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.